14 results about "Infection types" patented technology

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention provides a kit and a method for identifying the infection category of a sample to be detected by detecting host peripheral blood gene expression, the kit simultaneously detects expression levels of two groups of genes in the sample to be detected, the first group is genes for identifying bacterial infection, the group of genes are S100P gene, ANXA3 gene, ITGAX gene and ITGAM gene, and the group of genes are S100P gene, ANXA3 gene, ITGAX gene and ITGAM gene. The first group is a gene for identifying fungal infection, the second group is a gene for identifying fungal infection, the group comprises an IFI44L gene, an IFIT3 gene, an IFIH1 gene, an LY6E gene, an IFIT1 gene and an IFITM3 gene, and whether the sample to be detected is bacterial infection, fungal infection, simultaneous bacterial and fungal infection or non-bacterial and non-fungal infection is determined by detecting the two groups of genes. According to the invention, ten genes expressed in peripheral blood are screened out, so that the detection cost and accuracy for distinguishing bacterial infection and virus infection can be kept at a balance point, and finally, clinical application can be realized.

A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

This invention belongs to the field of biological detection technology, and particularly relates to a reproductive tract HPV-mRNA-E6 / E7 detection system and method based on nanopore sequencing. The system includes a sample pretreatment module, an RNA extraction and purification module, a reverse transcription module, a nanopore sequencing module, and a bioinformatics analysis module. The method includes the following steps: (1) reproductive tract sample collection and pretreatment; (2) extraction and purification of HPV-mRNA in the sample; (3) reverse transcription of the purified HPV-mRNA into cDNA; (4) nanopore sequencing of the cDNA to obtain raw sequencing data; (5) filtering, comparing, and annotating the sequencing data through the bioinformatics analysis module to achieve HPV type identification and quantitative analysis of E6 / E7 gene expression levels. This invention utilizes the advantages of nanopore sequencing, such as long read length and real-time detection, combined with the specificity of E6 / E7 mRNA as a biomarker of active infection. It can directly detect latent and active HPV infection, improve detection sensitivity, accurately distinguish infection types, and shorten the detection cycle. It enables rapid, accurate, and high-throughput detection of active HPV infection in the genital tract, providing reliable technical support for early screening, disease monitoring, and prognostic assessment of HPV-related diseases such as cervical cancer.

The invention discloses anti-infection type broken limb storage equipment, and relates to the technical field of broken limb storage, the anti-infection type broken limb storage equipment comprises a protection chamber, a buffer chamber is arranged at the bottom of the protection chamber, two exhaust parts are installed in the buffer chamber, a cooling chamber is installed at the bottom of the buffer chamber, a water scraping part is installed in the cooling chamber, a sterilization chamber is installed at the bottom of the cooling chamber, and a sterilization part is installed in the sterilization chamber; a driving motor is installed at the bottom of the sterilization chamber, a first gear is installed at the output end of the driving motor and meshed with the rotating part, and the sterilization part and the water scraping part are both installed on the annular surface of the rotating part. The buffer chamber, the cooling chamber and the sterilization chamber are sequentially installed at the bottom of the protection chamber, the exhaust structure composed of the cylinder, the first one-way valve, the second one-way valve, the piston and the connecting rod is installed in the buffer chamber, and cooled gas in the cooling chamber is evenly conveyed into the protection chamber through the exhaust structure; the temperature in the protection chamber is constant, water vapor is taken away timely, and the severed finger infection probability is reduced.

The invention provides an infectious fever antibacterial scheme selection method and system based on multi-dimensional data, and belongs to the technical field of infectious disease diagnosis and treatment. The method comprises the following steps: step (1), identifying a fever type based on symptom and sign data and inspection data, and positioning a pathogen type, an infection site and severity; (2) generating candidate antibiotic schemes based on the antibiotic knowledge base and a guide rule engine; (3) adjusting the dosage according to the individual parameters of the patient, and generating a first scheme and an alternative scheme; through multi-dimensional data integration, infection types are rapidly identified, antibiotics recommended by a guide are matched, and an accurate and safe antibacterial scheme (including a first scheme and an alternative scheme) is generated according to individual conditions of patients.

The invention relates to the technical field of keratitis detection systems, in particular to a detection system for rapidly diagnosing keratitis. The invention provides a detection system for rapidly diagnosing keratitis, which comprises a kit and an excitation light source, the kit comprises three independently packaged reagent single tubes; the three reagent single tubes comprise a first reagent single tube, a second reagent single tube and a third reagent single tube which are arranged in sequence according to a medication sequence; a reagent in the third reagent single tube comprises 6PD-DPAN; reagents in the first reagent single tube and the second reagent single tube are independently DO-DPAS or M1-DPAN, and the reagents in the first reagent single tube and the second reagent single tube are different; and the lambda ex of the excitation light source is equal to 200 to 420 nm. The detection system can simply, conveniently, quickly and accurately detect the infection type of keratitis.

The invention belongs to the field of biological detection, and particularly relates to an sgRNA and RPA primer group for synchronously detecting four porcine-derived viruses, a detection system and application. The sgRNA and RPA primer group for synchronously detecting the four porcine-derived viruses comprises a sgRNA and RPA primer group for detecting a porcine acute diarrhea syndrome coronavirus, a porcine rotavirus, a porcine transmissible gastroenteritis virus and a porcine epidemic diarrhea virus. The invention further provides a centrifugal micro-fluidic chip for synchronously detecting the four swine-derived viruses, the chip can be used for synchronously and highly specifically discriminating various swine-derived viruses and accurately distinguishing infection types in a single detection process, and a detection result has laboratory-level sensitivity and accuracy.

The application belongs to the field of biological detection, and particularly relates to sgRNA and RPA primer group, a detection system and application for synchronous detection of four pig-derived viruses. The sgRNA and RPA primer group for synchronous detection of four pig-derived viruses comprises sgRNA and RPA primer group for detecting porcine acute diarrhea syndrome coronavirus, porcine rotavirus, porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. The application further provides a centrifugal microfluidic chip for synchronous detection of four pig-derived viruses, which can be used to synchronously and highly specifically identify multiple pig-derived viruses and accurately distinguish infection types in a single detection process, and the detection result has both laboratory-level sensitivity and accuracy.

A method of selecting an exon of an RNA whose expression level is informative with respect to infection type of a subject is disclosed. The method comprises comparing the expression level of the RNA in a sample derived from a bacterially-infected subject and a sample derived from a virally-infected subject at a plurality of exons, wherein the exon that provides a differential expression between the bacterially-infected subject and the virally-infected subject above a predetermined level is selected as the exon of the RNA whose expression is informative with respect to infection type.

This invention provides a kit and method for identifying the infection type of a test sample by detecting gene expression in host peripheral blood. The kit simultaneously detects the expression levels of two groups of genes in the test sample. The first group consists of genes for identifying bacterial infection, including the S100P, ANXA3, ITGAX, and ITGAM genes. The second group consists of genes for identifying viral infection, including the IFI44L, IFIT3, IFIH1, LY6E, IFIT1, and IFITM3 genes. Detection of these two groups of genes determines whether the test sample is infected with bacteria, virus, a combination of bacteria and virus, or neither bacteria nor virus. This invention screens out 10 genes expressed in peripheral blood, achieving a balance between the cost and accuracy of distinguishing between bacterial and viral infections, ultimately enabling clinical application.

A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

A computer-implemented method determines an optimal drug dosing regimen to treat a patient against a drug-sensitive pathogenic agent responsible for infection. The method obtains patient data and drug data, including the drug, administration route, adaptation type (priori or posteriori), and a drug treatment regimen. The method includes determining values for pharmacokinetic parameters for efficacy (PPE) and pharmacokinetic parameters for toxicity (PPT) from the patient and drug data using population pharmacokinetic models when PPE and PPT are not obtained directly from measurement concentration(s). The method includes obtaining infection data, including parameters selected from the documentation of infection, localization, infection type, identified pathogen, susceptibility, and minimum inhibitory concentration. The method includes determining an efficacy target for the drug from the infection data and a target at risk of toxicity. The method includes determining an optimal dosing regimen by comparing PPE with the efficacy target and PPT with the risk of toxicity target.

The invention relates to an auxiliary diagnosis information output method and system. The method comprises the following steps: acquiring a first biological feature of a target object; inputting the first biological feature into a trained target recognition model for recognition, and determining a first recognition result; wherein the first recognition result is used for outputting auxiliary diagnosis information of the target object; the auxiliary diagnosis information comprises an infection type and a corresponding bacterial type when the infection type is bacterial infection; the infection types comprise non-infection, virus infection and bacterial infection. By adopting the method, not only can the infection type of the target object be identified, but also the specific infection bacterial type can be accurately identified when the infection type of the target object is bacterial infection, so that multi-level classification of infection information is realized, different types of infections can be more comprehensively, finely and intuitively distinguished, and the detection accuracy is improved. And an accurate auxiliary diagnosis information output result is provided for medical staff.